Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.

Meagan B RyanFerran Fece de la CruzSarah PhatDavid T MyersEdmond WongHeather A ShahzadeCatriona B HongRyan B Corcoran

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

These data identify feedback reactivation of wild-type RAS as a key mechanism of adaptive resistance to KRASG12C inhibitors and highlight the potential importance of vertical inhibition strategies to enhance the clinical efficacy of KRASG12C inhibitors.See related commentary by Yaeger and Solit, p. 1538.

Keyphrases

wild type
electronic health record
big data
risk assessment
climate change
artificial intelligence